Cormedix (CRMD) Stock Price, Quote, News & History | Benzinga

Cormedix Inc (CRMD) Stock Price, Quote, News & History

CRMDNASDAQ

Trade with Public

Trade with Public

$8.20

-0.03-0.36%

At close: Aug 21, 5:00 PM EST

$8.20

N/A

After Hours: Aug 21, 4:00 PM EST

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$8.29

Close

$8.20

Volume / Avg.

1.50M / 1.32M

Day Range

$8.15 - $8.41

52 Wk Range

6.13 - 14.96

Market Cap

$639.14M

P/E Ratio

3.78

Dividend Yield

-

Exchange

NASDAQ

RSI

55

Short Interest

21.17%

Days to Cover

17.1

Recent CorMedix Inc. News

CorMedix Stock Jumps on Strong DefenCath Sales

CorMedix Q2 earnings beat estimates as sales more than doubled, DefenCath revenue grew, and the company reaffirmed 2026 sales guidance.

Vandana Singh

Accelerant Holdings, CorMedix, Birkenstock And Other Big Stocks Moving Higher On Thursday

Nasdaq Composite gained 200 points on Thursday, while Accelerant Holdings (NYSE: ARX) rose 44.2% after being acquired by Thoma Bravo and reporting strong Q2 results. Other top gainers include Omeros Corp (NASDAQ: OMER), CorMedix Inc (NASDAQ: CRMD), and Hyliion Holdings Corp (NYSE: HYLN).

Avi Kapoor

Frequency Electronics Posts Weak Q4 Results, Joins AST SpaceMobile And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session

US stock futures mixed, Dow futures up 0.2%. Frequency Electronics (FEIM) shares down 8.3% after reporting Q4 losses. Other stocks also lower in pre-market.

Avi Kapoor

Nike, Shutterstock And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session

US stock futures lower as Dow falls 100 points. Nike shares down 4% after Q4 results. Shutterstock, Optimum Communications, Cronos, and others also drop.

Avi Kapoor

CorMedix Stock Jumps As DefenCath Fuels Q1 Beat, 2026 Outlook Raised

CorMedix raises 2026 guidance after Q1 revenue surges on strong DefenCath demand and higher profitability.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

253.94M

Investing Cash Flow (TTM)

-285.62M

Financing Cash Flow (TTM)

129.95M

Free Cash Flow (TTM)

250.42M

Capital Expenditure (TTM)

-3.52M

Net Change in Cash (TTM)

98.27M

Analyst Trends and Forecast

1

Mar

4

Apr

1

Jul

1

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.4

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$527.21M

PE Ratio (TTM)

3.78

PE Ratio (FWD)

15.24

PEG Ratio (TTM)

-

PS Ratio (TTM)

1.65

PB Ratio (TTM)

1.39

Earnings Yield % (TTM)

26.49%

Earnings Yield % (FWD)

6.56%

EV / EBITDA (TTM)

2.08

Price / EBITDA (TTM)

2.95

Price / Free Cash Flow (TTM)

3.00

Book Value / Share

$5.91

Company Debt

Total Debt

$145.15M

LT Debt

$145.15M

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$256.69M

Debt to Equity

0.31

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$8.29

Close

$8.20

Volume / Avg.

1.50M / 1.32M

Day Range

$8.15 - $8.41

52 Wk Range

6.13 - 14.96

Market Cap

$639.14M

P/E Ratio

3.78

Dividend Yield

-

Exchange

NASDAQ

RSI

55

Short Interest

21.17%

Days to Cover

17.1

About

Sector

Health Care

Industry

Pharmaceuticals

Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States a...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Cormedix (CRMD) stock?

A

You can purchase shares of Cormedix (NASDAQ:CRMD) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Cormedix (CRMD) competitors?

A

Other companies in Cormedix’s space includes: Eli Lilly and Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co Inc (NYSE:MRK), Novartis AG (NYSE:NVS) and AstraZeneca PLC (NYSE:AZN).

Q

What is the forecast, or price target, for Cormedix (CRMD) stock?

A

Cormedix has a consensus price target of $15.64.

Q

What is the current price for Cormedix (CRMD)?

A

The stock price for Cormedix (NASDAQ: CRMD) is $8.2 last updated August 21, 2026 at 4:00 PM EDT.

Q

Does Cormedix (CRMD) pay a dividend?

A

There are no upcoming dividends for Cormedix.

Q

When is Cormedix (NASDAQ:CRMD) reporting earnings?

A

Cormedix does not have any upcoming earnings scheduled.

Q

Is Cormedix (CRMD) going to split?

A

There is no upcoming split for Cormedix.

Q

What sector and industry does Cormedix (CRMD) operate in?

A

Cormedix is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.